Progress Regarding Parkinson's Disease Psychosis: It's No Illusion

Overview

Journal Mov Disord Clin Pract

Publisher Wiley

Specialty Neurology

Date 2018 Oct 27

PMID 30363521

Citations 2

Authors

Daniel Weintraub

Affiliations

Soon will be listed here.

Citing Articles

Gupta R, Gothwal M, Lenka A, Kamble N, Yadav R, Arumugham S Ann Indian Acad Neurol. 2025; 28(1):92-98.

PMID: 39746843 PMC: 11892954. DOI: 10.4103/aian.aian_687_24.

Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms.

Zhang S, Ma Y World J Psychiatry. 2022; 12(9):1127-1140.

PMID: 36186499 PMC: 9521528. DOI: 10.5498/wjp.v12.i9.1127.

Psychosis in parkinsonism: an unorthodox approach.

Onofrj M, Carrozzino D, DAmico A, Di Giacomo R, Delli Pizzi S, Thomas A Neuropsychiatr Dis Treat. 2017; 13:1313-1330.

PMID: 28553118 PMC: 5439966. DOI: 10.2147/NDT.S116116.

References

Kurita A, Murakami M, Takagi S, Matsushima M, Suzuki M . Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord. 2010; 25(2):167-71. DOI: 10.1002/mds.22919. View

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A . Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015; 30(7):919-27. PMC: 4855523. DOI: 10.1002/mds.26170. View

Ondo W, Tintner R, Voung K, Lai D, Ringholz G . Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005; 20(8):958-63. DOI: 10.1002/mds.20474. View

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A . Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2013; 383(9916):533-40. DOI: 10.1016/S0140-6736(13)62106-6. View

Mack J, Rabins P, Anderson K, Goldstein S, Grill S, Hirsch E . Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2011; 20(2):123-32. PMC: 3168582. DOI: 10.1097/JGP.0b013e31821f1b41. View

. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999; 340(10):757-63. DOI: 10.1056/NEJM199903113401003. View

Ballanger B, Strafella A, van Eimeren T, Zurowski M, Rusjan P, Houle S . Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010; 67(4):416-21. DOI: 10.1001/archneurol.2010.35. View

Schrag A, Horsfall L, Walters K, Noyce A, Petersen I . Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 2014; 14(1):57-64. DOI: 10.1016/S1474-4422(14)70287-X. View

Ortoll R, PAULSON G . Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996; 53(12):1265-8. DOI: 10.1001/archneur.1996.00550120077019. View

10.

McKeith I, Dickson D, Lowe J, Emre M, OBrien J, Feldman H . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12):1863-72. DOI: 10.1212/01.wnl.0000187889.17253.b1. View

11.

Weintraub D, Chiang C, Kim H, Wilkinson J, Marras C, Stanislawski B . Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. JAMA Neurol. 2016; 73(5):535-41. PMC: 5157923. DOI: 10.1001/jamaneurol.2016.0031. View

12.

Rabey J, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C . Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2006; 22(3):313-8. DOI: 10.1002/mds.21116. View

13.

Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H . Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism Relat Disord. 2012; 19(3):295-9. DOI: 10.1016/j.parkreldis.2012.10.022. View

14.

Fernandez H, Aarsland D, Fenelon G, Friedman J, Marsh L, Troster A . Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008; 23(4):484-500. DOI: 10.1002/mds.21875. View

15.

Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L . The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010; 25(6):763-6. PMC: 2891710. DOI: 10.1002/mds.22839. View

16.

Fenelon G, Goetz C, Karenberg A . Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006; 66(1):93-8. DOI: 10.1212/01.wnl.0000191325.31068.c4. View

17.

Manganelli F, Vitale C, Santangelo G, Pisciotta C, Iodice R, Cozzolino A . Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain. 2009; 132(Pt 9):2350-5. PMC: 2800383. DOI: 10.1093/brain/awp166. View

18.

Goetz C, Fan W, Leurgans S, Bernard B, Stebbins G . The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006; 63(5):713-6. DOI: 10.1001/archneur.63.5.713. View

19.

Aarsland D, Larsen J, Cummins J, Laake K . Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999; 56(5):595-601. DOI: 10.1001/archneur.56.5.595. View

20.

Ramirez-Ruiz B, Marti M, Tolosa E, Falcon C, Bargallo N, Valldeoriola F . Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Mov Disord. 2008; 23(16):2335-43. DOI: 10.1002/mds.22258. View